Advances in the Use of MRI in the Management of MS. The Role of MRI in MS Management. Jack H. Simon Portland, Oregon
|
|
- Amberly Reeves
- 8 years ago
- Views:
Transcription
1 Advances in the Use of MRI in the Management of MS The Role of MRI in MS Management Jack H. Simon Portland, Oregon
2 Disclosures Dr. Simon has nothing to disclose. This continuing education activity is managed and accredited by Professional Education Services Group in cooperation with the Paralyzed Veterans of America. Neither PESG nor PVA nor any accrediting organization supports or endorses any product or service mentioned in this activity. PESG Staff and the Program Planning Committee have no financial interest to disclose. Commercial Support was not received for this activity.
3 MRI in the Individual Patient As Opposed to the MS Patient Population
4 The Role of MRI in MS Management MRI in Diagnosis/Differential Diagnosis McDonald-International Criteria/CIS/RIS Technique Standardized Imaging New Techniques/Technologies Measures of Disease & Disease Activity Monitoring Sub-Clinical Change Over Time Evaluating Treatment Outcome-Responding? Detecting Complications of Treatment
5 Why Conventional MRI in (MS) Clinical Practice? Advantages Sensitive to early and subclinical disease Measure of pace of disease Objective, Informative, Predictive Detects concurrent pathology - complications of therapy Limitations T2- lesions Non-specific with regard to pathology Gd lesions Only a subclass & fraction of inflammation Indirect sensitivity to neurodegeneration (atrophy) Blind to details of axons, myelin, cells, chemistry But -qmri is not (yet) effective in individuals
6 Number Lesions The Disease is Largely Subclinical MR Event Rate >>>>>>Clinical Attack Rate CIS Time (months) Zero Attacks
7 Baseline-CIS 12 month 18 month No Clinical Event over 5 years - Cognitive Deficits The Focal Sub-Clinical Changes Are Relevant
8 Example--What we cannot see What we can see
9 Pre-Imaged Stage Group avg MTR or 1/T2 etc Lesion Image Stage Gd+ / T2 + Follow-up Imaging T2 + T2 Footprint Goodkin et al, 1998
10 The T2 Footprint is Stable Over Time time A Strong Measure of Sub-Clinical Activity Within a Given Interval
11 Problem Gd-enhanced MRI in an Individual is only a Snapshot in Time Monthly MRI s over a year Goodkin, Rooney, Sloan, et al Neurol. 98
12 Enhancing Lesion Counts After a CIS Fred Barkhof et al Amsterdam
13 Enhancing lesion number Enhancing Lesion Count in Untreated MS Patient CEL month Courtesy of Nancy Richert
14 Atrophy as a Measure of Neurodegeneration Baseline Two Years Later BPF Fisher et al, 2002
15 Example Case 12 Years of Data July Atrophy Pattern: Decelerating Male RRMS Symptom duration: 13.4 years Baseline (July 2000) Last Visit (Sept 2012) Age: EDSS: 1 3 MSFC: BPF courtesy Beth Fisher Sept 2012
16 BPF in Individual Patients Over 12 months Courtesy E. Fisher & R. Rudick
17 BPF Change Over 12 Years in 4 MS Patients 49 F; RRMS; EDSS F; RRMS; EDSS F; RRMS; EDSS 3 65 M; SPMS; EDSS 4 courtesy Beth Fisher
18 Classic Spinal Cord Pathology in MS Vertically oriented A few segments (remember 2 or fewer) Multicentric - Multiple lesions May enhance Partial cross-sectional involvement Dorsal-lateral surfaces Cord can be enlarged in acute stages Atrophy
19 Spinal Cord --- Classic Appearance
20 Spinal Cord --- MS Proton/T2 Proton density
21 Spinal Cord Atrophy
22 Spinal Cord MRI for Differential Diagnosis MS Non-specific Non-specific T2-hyperintensities are very rare in normal spinal cord (including from aging and in patients with cardiovascular risk factors) From Bot et al., 2002
23 Presents with episode of severe myelopathy Brain MRI negative Courtesy Tony Traboulsee, UBC
24 Neuromyelitis Optica NMO IgG Seropositivity Antibody Against Aquaporin-4 Water Channel AQP-4 receptors reside on the astrocyte foot-processes
25 Patient with severe bilateral optic neuritis
26 3 months later - after spinal cord symptoms develop
27 Monitoring Therapy in The Individual MS Patient Art Becoming Science
28 Enhancing lesion number 1 Lesion Counts Proof of Concept - Monitoring Therapy T2LL (cc) IFN CEL T2LL month Courtesy of Nancy Richert
29 Evaluating Treatment Response by MRI? But MONTHLY MRI IMPRACTICAL Good Response Continue Rx Initiate Therapy MRI or Clinical Criteria? Poor Response (Non- Responder) Consider Change in Therapy Second Line Therapy Are there objective criteria for non-responder?
30 Selected Evidence-Based Studies to Define Treatment Failure Rudick et al (2004) Rio et al (2008) Durelli et al (2008) Kinkel et al (2008) Gd/New T2 /Relapse Active Lesions (N,E,Gd+) Active MRI and NAb Gd+ and T2 Based on different validating outcome measures and classification parameters
31 Can Response to Therapy Be Determined Early and Based on a Single MRI Study? Clinically Isolated Syndrome Positive MRI Evaluate MRI Activity At 6 Month Study Hi Lesion Count Cutpoints Low Count Cutpoints Validation by Outcome Measure (CDMS) By Three Years Kinkel et al, 2008
32 Single MRI Evaluation at Six Months Post Therapy Predicts Outcome in Treated Patients Kinkel et al, 2008 Months after CIS Hi Co Cutpo Low C Cutpo Treated Group Hazard Ratio = 4.99 (p <0.0001)
33 Year 1and Year 2 MRI.15 Year Disability Outcome Bermel et al 2012
34 Worst Quartile of EDSS after 15 Years GD+.Odds Ratio 8.96 (p <0.001) Bermel et al 2012
35 SURVEILLANCE MRI for COMPLICATIONS OF THERAPY of MS
36 Progressive Multifocal Leucoencephalopathy (PML) in MS Treated with Natalizumab Prevalence vs Infusions As of May 3, 2012, approximately 99,600 patients received natalizumab worldwide, with 242 cases of PML reported. Clifford et al, Lancet 2010
37 Progressive Multifocal Leucoencephalopathy (PML) Prognosis for PML has been Poor Discover-Plasmapharese-Antivirals Charil, 2006
38 Difficulty is Detecting PML Within the background of MS Lesions Adapted from Nancy Richert
39 Detecting PML With MS in the Background Slice #1 Slice #1 MS CENTRAL PML PERIPHERAL
40 Slice #1 Slice #2 Adapted from Nancy Richert
41 DWI - Relatively More Positive in PML v MS MS DWI T2 Shine Through PML DWI Greater T2 Shine through? Adapted From Nancy Richert
42 PML Rapid Increase!!!!!!
43 Peripheral, Subcortical; Ill defined borders From Nancy Richer
44 PML Generally no mass effect Ill defined, or linear enhancement possible, not the total lesion area
45
46 Asymptomatic PML Detected Through Surveillance MRI From Demasters et al, 2012
47 VARICELLA-ZOSTER VIRUS ENCEPHALITIS AND VASCULOPATHY IN A PATIENT TREATED WITH FINGOLIMOD Ratchford J N et al. Neurology 2012;79:
48 IMPROVED & STANDARDIZED TECHNIQUE
49 STANDARDIZED MRI in MS Update T. Traboulsee et al In 2009 Mscare.org 3D Acquisition Improves the Interface for Standardized Acquisition and Interpretation
50 Eur Radiol 2008
51 3D SEQUENCES DIR FLAIR T2 MPRAGE
52 Gray Matter Demyelination Double Inversion Recovery- DIR Images from six month follow-up; From Calabrese, Neuroimage, 2008 Geurts, 2005, reported in Radiology a 500% advantage over T2; 150% over FLAIR
53 Counting New T2 Lesions in the Cortex? Calabrese Arch Neurol. 2007
54 3D FLAIR Sagittal Acquisition 1mm partitions 3T MRI
55 Axial Reconstruction From Sagittal Acquisition
56 PD/T2 3D FLAIR
57 Subtraction MRI ---Activity Predicts Atrophy Time 1 Time 2 Subtraction Image Liquori et al
58 Summary -The Role of MRI in MS Management Simple Measures T2, Gd, Atrophy Sensitive to Subclinical Disease Activity Evaluating Response to Therapy Art - Becoming Science Improved Clinical Care MRI in Early Detection of Complications of Therapy Implementing Stronger Technique 3D Acquisition
59 THE END
60
61
62
63 PML Rapid Increase!!!!!!
64 Peripheral, Subcortical; Ill defined borders; From Nancy Richer
65 PML Generally no mass effect Ill defined, or linear enhancement possible, not the total lesion area
66 RRMS- 169 patients classified IFN-beta 1a 3 Classification parameters for non responder Relapses in 2yr cutoff 2 or more Gd+ lesions (yr 1 + yr2) cutoff 2 or more New T2 at yr 2 (versus baseline)- cutoff 3 or more Outcome based on EDSS, MSFC, BPF
67
68
69
70 Correia et al. Neuroimage yo Healthy Control 60 yo Vasc. Cog. Impaired Length & Number of Streamtube based Metrics
71 One Patient Pre/Post-Corpus Callosotomy
72 MRI Signal and Field Strength 3T scanner should have twice SNR of 1.5T scanner 7T should have ~4.7 times SNR of 1.5T. Modified from C.Rorden, www From: F. Fera et.al., J MRI 19:19-26 (2004)
73 7 Tesla MRI - MS T2*W Imaging Advanced Imaging Research Center AIRC, OHSU Courtesy, Dan Pelletier, UCSF
74 Standardized MRI Guidelines PD optional Recommended
75
76 Figure. Examples of double inversion recovery (DIR) images with white matter and cortical lesions. Papadopoulou A et al. Mult Scler 2013; Copyright by SAGE Publications
77 Double Inversion Recovery Images from six month follow-up; From Calabrese, Neuroimage, 2008 Geurts, 2005, reported in Radiology a 500% advantage over T2; 150% over FLAIR
78 Counting New T2 Lesions in the Cortex? Calabrese Arch Neurol. 2007
Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of MRI in Diagnosing and Monitoring MS Jack H. Simon, Portland, OR
Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of MRI in Diagnosing and Monitoring MS Jack H. Simon, Portland, OR What MRI Taught Us about Neurodegeneration and MS Matilde Inglese, NewYork MRI
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationUpdate: MRI in Multiple sclerosis
Nyt indenfor MS ved MR Update: MRI in Multiple sclerosis Hartwig Roman Siebner Danish Research Centre for Magnetic Resonance (DRCMR) Copenhagen University Hospital Hvidovre Dansk Radiologisk Selskabs 10.
More informationMRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationSensitive and reproducible clinical rating
CLINICAL AND MRI MARKERS OF MS DISEASE PROGRESSION * Richard A. Rudick, MD ABSTRACT Sensitive and reproducible measures of multiple sclerosis (MS) severity and progression are important in the treatment
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationTreatment Optimization in MS: When to Start, When to Shift, when to Stop
Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital
More information2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationUsing the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
More informationRational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València
Rational basis for early treatment in MS Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Bonaventura Casanova Department of Neurology University Hospital La
More informationMRI in drug development: Lessons from MS
MRI in drug development: Lessons from MS Douglas L. Arnold MD McConnel Brain Imaging Center, MNI, McGill NeuroRx Research Inc Drug development Pre-clinical Phase I Phase II Phase III Phase IV Candidate
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationGuidance for evaluation of new neurological symptoms in patients receiving TYSABRI
Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Background information Progressive multifocal leukoencephalopathy (PML) PML is a demyelinating disease that attacks the
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationAdvanced Multiple Sclerosis: Progressive MS Epidemiology
Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationThe role of MRI in modern management of and treatment decisions in MS
The role of MRI in modern management of and treatment decisions in MS franz.fazekas@medunigraz.at Vienna, September 25, 2013 Department of Neurology, http://neurologie.uniklinikumgraz.at Disclosures 8
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationProgress in the field: therapeutic improvements for all patients?
Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination
More informationNatalizumab and the Risk of PML
Natalizumab and the Risk of PML Gloria von Geldern, MD Multiple Sclerosis Center Assistant Professor of Neurology University of Washington May 13, 2015 Conflict of Interest Dr. von Geldern has nothing
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationSupplementary Online Content
Supplementary Online Content Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting
More informationMS: The Treatment Paradigm, A Pathway to Success for Improved Patient Outcomes
MS: The Treatment Paradigm, Pathway to Success for Improved Patient Outcomes Jack Burks, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title.
More informationGrand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com
Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management CME University, FreeCME.com, Powerpak.com Faculty Clyde E. Markowitz, MD Associate Professor of Neurology Director, Multiple
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationMULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.
MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics Disclosures I do not have any disclosures. Multiple Sclerosis Most
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationMultiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationMULTIPLE SCLEROSIS 2015. Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine
MULTIPLE SCLEROSIS 2015 Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine Disclosure Research support, Sunovion and Marinus for epilepsy research Goals and Objectives
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationAccuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
More informationIII./5.3.: Multiple sclerosis. Epidemiology. Etiology. Pathology
III./5.3.: Multiple sclerosis Epidemiology Multiple sclerosis (MS) is the most common neuroimmunological disorder of the central nervous system. This chronic illness begins in early adulthood, mostly at
More informationSTARTING AND SWITCHING MULTIPLE SCLEROSIS THERAPY
STARTING AND SWITCHING MULTIPLE SCLEROSIS THERAPY Steven Galetta, MD University of Pennsylvania Philadelphia, PA LEARNING OBJECTIVES 1. The attendee will be able to describe the features of the radiologically
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationTrauma Insurance Claims Seminar Invitation
Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationA Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Association Between Immediate Initiation of Intramuscular Interferon Beta-a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes A -Year Follow-up of the Controlled
More informationNeurosarcoidosis. Jeffrey M. Gelfand, MD
Neurosarcoidosis WASOG Meeting Cleveland October 2012 Patient Education Session Relevant Financial Disclosures: None Jeffrey M. Gelfand, MD Assistant Professor of Clinical Neurology UCSF MS Center, Dept
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationUse of imaging in multiple sclerosis
CHAPTER 3 Use of imaging in multiple sclerosis M. Filippi, 1 M. A. Rocca, 1 D. L. Arnold,2 R. Bakshi,3 F. B ar khof, 4 5 N. De Stefano, F. Fazekas,6 E. Frohman,7 D. H. Mil le r, 8 9 J. S. Wolinsky 1 Institute
More informationClinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationApplication of Interferon Beta-1b in Multiple Sclerosis. Francesca Bagnato, MD, PhD
Application of Interferon Beta-1b in Multiple Sclerosis Francesca Bagnato, MD, PhD Visiting Assistant Professor of Radiology and Radiological Sciences, Vanderbilt University Institute of Imaging Science
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationPLEX: For whom and how? Current and potential uses for MS and NMO
PLEX: For whom and how? Current and potential uses for MS and NMO Brian G. Weinshenker MD, FRCP(C) Rochester MN Disclosures Royalties related to patent for discovery of NMO-IgG licensed to RSR, Ltd. Consulting
More informationHow To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
More informationMultiple Sclerosis Jeffrey M. Gelfand, MD
Multiple Sclerosis Jeffrey M. Gelfand, MD UCSF Multiple Sclerosis Center SFGH Neuroimmunology Clinic UCSF and SFGH Departments of Neurology Goals To review the fundamentals of neurological localization
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationInforming Decisions to Improve the Continuum of Care in Relapsing-Remitting Multiple Sclerosis
Informing Decisions to Improve the Continuum of Care in Relapsing-Remitting Multiple Sclerosis Mirla Avila, MD Texas Tech University Health Sciences Center, Lubbock, Texas Abstract Disease-modifying therapy
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationCurrent Industry Neuroimaging Experience in Clinical Trials Jerome Barakos, M.D.
Current Industry Neuroimaging Experience in Clinical Trials Jerome Barakos, M.D. Melbourne Australia March 28, 2012 Synarc Experience and Expertise Largest imaging service provider dedicated to clinical
More informationFeatured Cases: Personalizing DMT Regimens/The Risks Of Medication Non-Adherence
HOME NEWSLETTER ARCHIVE CME INFORMATION PROGRAM DIRECTORS EDIT PROFILE RECOMMEND TO A COLLEAGUE VOLUME 1 ISSUE 2: TRANSCRIPT Featured Cases: Personalizing DMT Regimens/The Risks Of Medication Non-Adherence
More information09/05/2014. Painting pictures of the brain with numbers. Overview
Painting pictures of the brain with numbers Neurology for Insurers Dr Ian Cox & Adele Groyer (Gen Re) Overview Critical Illness Product Background Why should we be interested in neurology? Consult our
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationBuilding on Leading Market Positions
Building on Leading Market Positions Bharat Tewarie Head of Global Business Franchise Neurodegenerative Diseases Darmstadt, May 15, 2012 Agenda 1. Introduction 2. Rebif: Defending the franchise 3. Fertility:
More informationTreatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
More informationQuantitative Assessment of MRI Features in Patients with Relapsing-Remitting Multiple Sclerosis
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, August 2014. Vol. 11(2), 863-868 Quantitative Assessment of MRI Features in Patients with Relapsing-Remitting Multiple Sclerosis Babak Shekarchi 1, Samaneh Fartook
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationMultiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationDisclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.
Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationfingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK
fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationMultifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD
Multifocal Motor Neuropathy Jonathan Katz, MD Richard Lewis, MD What is Multifocal Motor Neuropathy? Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationMultiple sclerosis (MS) is an
CLINICALLY ISOLATED SYNDROME: EVALUATION, RISK STRATIFICATION, AND TREATMENT DECISIONS * Bruce Cree, MD, PhD, MCR, and Timothy L. Vollmer, MD ABSTRACT Recently a group of community and academic neurologists
More informationUncertainty in Benefit and Risk: Tysabri (natalizumab)
Uncertainty in Benefit and Risk: Tysabri (natalizumab) Robert J. Temple, M.D. Deputy Center Director for Clinical Science Center for Drug Evaluation and Research U.S. Food and Drug Administration IOM Drug
More informationTITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationThe Evolution of In Vivo Confocal Microscopy for Quantitative Corneal Imaging W. Matthew Petroll, Ph.D.
Genetics in Eye Disease: From Discovery to Clinical Applications Lucia Sobrin, MD, MPH I. Introduction a. Mendelian Genetic Diseases i. Sequencing b. Complex Polygenic Diseases i. Genome-wide association
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationMultiple Sclerosis - Relapsing and Remissioning
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationClinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
More informationNew Horizons in Multiple Sclerosis Management
Disclosures New Horizons in Multiple Sclerosis Management Jody Corey-Bloom, MD, PhD University of California, San Diego Principal Investigator on numerous clinical trials for dementia; support from various
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationClinical Features and Treatment Outcomes in MS An Update from Contemporary Cohorts
Clinical Features and Treatment Outcomes in MS An Update from Contemporary Cohorts PVA Summit August 2013 Orlando, FL Mitchell T. Wallin, MD, MPH Clinical Associate Director VA MS Center of Excellence
More information